Radioisotopes that emit electrons (beta particles), such as radioiodine, can effectively kill target cells, including cancer cells. 
Introduction
Beta particles (electrons) emitted by radioisotopes are known to efficiently kill cancer cells. This finding has already been clinically exploited by using 131 I to treat thyroid cancer [1] , a strategy still employed successfully in more than 50% of such patients in the United States, with over a 90% cure rate. Similarly, beta particle-emitting radiolabeled antibodies directed against CD20, including have been used against non-Hodgkin's lymphoma [2, 3] . Moreover, 90 Y-labeled somatostatin receptor ligand is utilized to treat neuroendocrine tumors [4] . Electrons emitted by 32 P have an energy level intermediate between those of 131 I and the more powerful 90 Y, resulting in a path length of up to 5 mm in human tissues [5] . Electrons emitted from radioisotopes can strike thousands of cells. The resulting bystander effect amplifies the lethal potential of each beta particle emitted in or near a tumor. However, as we shall show below, we have discovered that among all available beta-emitting isotopes, 32 P possesses a unique chemically and radiologically-based double-strand breakage mechanism, which confers greater anti-tumor efficacy than other beta-emitters of comparable power.
Human cancer-derived cell lines established in immunocompromised mice are a valuable tool for testing the effectiveness of candidate anti-cancer agents [6] [7] [8] [9] . We previously found that a single, low-dose intravenous injection of [ 32 P]ATP significantly inhibits tumor growth for several weeks in murine xenograft models [10, 11] . Because ATP is a small naturallyoccurring molecule, its radiolabeled form poses some advantages over larger synthetic compounds as a potential anti-cancer therapeutic, including lower immunogenicity, greater tumor penetration, and superior pharmacokinetics [12] . Inorganic [ 32 P]PO 4 , a simple aqueous ion, has been used for decades as a therapeutic agent for polycythemia vera and essential thrombocythemia [13] . This ion was also previously used for palliation of bone pain due to metastases, where it was thought to be incorporated into the extracellular matrix [14] . However, aqueous 32 P use has never been established as a primary anti-cancer strategy per se.
The clinical application of 32 P was first attempted in the 1930's [15] [16] [17] [18] . Since that time, 32 P usage has generally been restricted to a colloidal suspension form, wherein 32 P forms a component of a complex, insoluble particle [19] [20] [21] [22] . This form of 32 P is typically injected directly into the tumor, with the colloidal suspension preventing the radioisotope from leaving the intended target and disseminating throughout the body. The administration of aqueous 32 P as a primary anti-cancer agent has not been studied, aside from its palliative use for relief of pain due to bone metastases.
Recent experimental findings have led to the development and use of the alpha-and betaemitter 223 Ra to selectively target bone metastases in patients with castration-resistant prostate cancer [23, 24] . Originally developed by a Norwegian company Algeta, Alpharadin was approved for use in the United States in 2013, and is now marketed by Bayer under the name Xofigo [25] . Thus, 223 Ra is the latest simple radioactive element to become an effective anticancer drug.
We now report that a single, low-dose intravenous injection of aqueous 32 Assay for apoptosis in cell lines incubated with 32 
P.
One hundred thousand mouse CRL2836 cells or HeLa S3 cells were seeded into each well of 6-well culture plates and grown for 24 h. Cells were then incubated with 0, 2.5, 5, 10 or 20 uCi 32 P[PO 4 ] in two ml complete medium for 24 h, and non-radioactive medium added for an additional 24 h. Protein was extracted from each well using RIBA buffer (Cell Signaling Technology, Boston, MA), the protein was quantified using a BCA protein assay kit (Pierce, Rockford, IL),and identical quantities were run on a 10 to 20% polyacrylamide gel, and blotted to nitrocellulose. A western blot using a primary antibody to cleaved caspase-3 protein (Cell Signaling Technology, Boston, MA) was used to assay for apoptosis. A second western blot with identical protein quantities was probed with antibody against beta-actin (Cell Signaling Technology, Boston, MA).
Establishment of mouse tumors
Syngeneic BALB/c mouse tumors were established by injecting 2 X 10 6 BALB/c tumor CRL2836 cells (American Type Cell Culture, Manassas, VA) in a volume of 0.2 mL (50% Matrigel, 50% 1 X PBS) subcutaneously in the left rear and right rear flank. All mice were female, 10 weeks of age, and purchased from Charles River Laboratories (Wilmington, MA). 
Statistical analysis
The data from the WST-1 cell proliferation were presented as means ± standard deviation, and the significance was determined using the unpaired Student's t test. Tumor volumes of the untreated and treated mice were displayed as means ± SE; no outliers were excluded for any reason. Significance was determined using the unpaired Student's t test.
Results
Cells exposed to [ 32 P]PO 4 were compared with those exposed to identical counts per minute of the more powerful beta-particle emitter, 90 Y, after which WST-1 cell proliferation assays were performed (Fig 1) . Different cell lines were expected to demonstrate varying levels of susceptibility to radioisotopes. The 1 μCi dose showed that HeLa cells were less susceptible to betaemitting isotopes than were BALB/c mouse CRL2836 cells, which originated as an osteosarcoma and were isolated after it had metastasized to lung. Both the 2. The H2AX assays were used to compare double-strand DNA breakage in cells incubated with 32 P vs. 90 Y (Fig 2) [26, 27] . This assay accurately detects breakage in both strands of DNA at the same genomic locus. Nuclear staining of HeLa S3 cells demonstrated substantial, timedependent double-strand DNA breakage in cells exposed to 32 P, while those exposed to identical levels of 90 Y-based radiation had much less or no detectable DNA double-strand breakage.
Digestion with DNase I showed that administered 32 P had been directly incorporated into cellular DNA (Fig 3A) . More than half of the 32 P retained by the cells that were incubated with 32 P[PO 4 ]for 24 h and then grown in non-radioactive medium for 48 h before the DNA was extracted had been permanently incorporated into cellular DNA. To determine whether cell death involves apoptosis as well as necrosis, mouse CRL2836 cells or HeLa S3 cells were incubated with varying amounts of 32 P for 24 hours, replaced with non-radioactive medium for an additional 24 hours, and the cells analyzed by western blot for the presence of cleaved caspase-3 indicating apoptosis (Fig 3B) . The CRL2836 cells clearly demonstrated that apoptosis was involved in cellular death, while the HeLa S3 cells showed no detectable cleaved caspase-3 (data not shown). Antibody directed against beta-actin was used to verify equal loading of protein amounts in the gel wells. HeLa S3 cells express E6 from HPV18 and are rendered p53 null which severely inhibits apoptosis functions [28, 29] . Previously, we demonstrated significant inhibition of HeLa S3 cell xenograft growths in nude mice by a single low-dose intravenous (IV) injection of [ 
Discussion
This study documents our discovery that a single intravenous dose of the 32 P radioisotope significantly inhibits the growth of pre-established tumors in a murine syngeneic model, while simultaneously establishing the mechanism underlying this anti-cancer effect. Specifically, we show that aqueous 32 P is incorporated into nascent DNA, where isotopic decay shears both strands, causing double-strand breakage as proven by phosphorylation of the histone H2-AX. Our in vitro experiments also demonstrate that the pure beta-emitter 32 P is superior to the more powerful pure beta-emitter 90 Y in tumor cytotoxicity, and finally, that apoptosis contributes to this cytotoxicity. Fig 5 depicts a proposed mechanism for 32 P-induced cell killing. In this schematic, 32 P is incorporated directly into one strand of replicating DNA. Radioactive decay of 32 P to 32 S causes chemical breakage of that same DNA strand. Next, the electron released by this decay event needs to travel only 2 nm to reach the contralateral strand of the double helix, severing it and thus causing a double-strand break at this genomic locus. This mechanism stands in stark contrast to non-incorporated beta-emitting radioisotopes, where only a small fraction of emitted electrons travel in the precise orientation necessary to strike one strand plus its opposite strand and cause a double-strand DNA break [30, 31] . With 32 P, the extreme proximity of the contralateral target strand to the decay-produced electron makes this double-strand breakage much more likely to occur [32] . [36] . In this context, it is noteworthy that no obvious toxic side effects occurred in any of the model systems we have studied to date. The other concern with its use in these benign hematologic disorders has been an increased incidence of subsequent acute myeloid leukemia (AML) [37, 38] , but in patients with advanced solid tumors this is less of a concern, since subsequent AML occurs in only 10% ten years after 32 P treatment [39] . Moreover, this new indication and method of use for an existing drug saves considerable time and expense, relative to the investment required for new anticancer agents. Thirdly, in contrast to other beta-emitting isotopes such as 131 I and 90 Y, 32 P is incorporated directly into nascent DNA [40, 41] . Our data suggest that this incorporation dramatically increases the cell-killing efficiency of 32 P, since the decay of incorporated 32 P to sulfur chemically breaks the first strand of the DNA and the released electron needs to travel only 2 nm to reach its contralateral DNA strand. Thus, this process efficiently causes double-strand DNA breakage, which is required to overcome innate DNA repair pathways and achieve cell death. In contrast to 32 P, other electron-emitting isotopes (such as
131
I and 90 Y) emit electrons from distances of 1,000 to 5,000 nm away from DNA, some 500-to 2,500-fold farther than the distance of an incorporated 32 P atom from its sister DNA strand [42] [43] [44] . 12) . The extracted nucleic acids were incubated with DNase I, the digestion products were run on a 5% polyacrylamide gel and exposed to film. B. Apoptosis induced by 32 P in mouse CRL2836 cells. Mouse CRL2836 cells were incubated with 0, 2.5, 5, 10 or 20 μCi 32 P[PO 4 ] for 24 h, and non-radioactive medium added for an additional 24 h. Protein was extracted from each well and analyzed for apoptosis by western blots using antibody to cleaved caspase-3 protein (Lanes 1 through 5). Antibody against beta-actin was used to verify identical amounts of protein were loaded (lanes 6 through 10). doi:10.1371/journal.pone.0128152.g003
Inhibition of Mouse Tumor Growth by Elemental 32P Isotope
It is intriguing to note that early researchers performing Sanger sequencing with [ 32 P]dATP in the 1980's noted that sequencing products required electrophoresis within two days after the sequencing reaction, otherwise bands seemed to disperse and were difficult to interpret [45] . This same principle may operate with 32 P as an anti-cancer agent. The decay of 32 P to sulfur chemically shears the strand of DNA into which it is incorporated. We hypothesize that this event, coupled with the extremely close proximity of the incorporated radioisotope to its sister DNA strand, results in a dramatic increase in cell-killing efficiency vs. other beta-particle emitters such as The radioisotope is incorporated into the ribose-phosphate backbone of DNA in dividing cells. The process of decaying to sulfur ( 32 S) breaks the backbone bond of the initial strand at a 67% rate and releases a high energy beta particle (electron) that must only travel two nm across the helix to the opposite target strand. Although an emitted electron that travels in the perfect orientation from this 32 P decay to sever the opposite strand will only occur at a low percentage of the time, it is still much higher and more efficient than those electrons which are generated by other beta-producing radioisotopes on the cell surface or in the cytosol that must travel distances that are usually one thousand times or more longer in length.
doi:10.1371/journal.pone.0128152.g005
